slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 4,651-4,680
Pages 350
Rows per page 30
Slide type
4,651-4,680 of 10,471
24
CIAS likely refers to Cognitive Impairment Associated with Schizophrenia.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
05
BenevolentAI | Investor Presentation Deck | 46 slidesBenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
13
The chart uses a horizontal bar format to represent progress through clinical phases. Several programs are marked with AstraZeneca partnership dates.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
14
The slide uses a split-layout with a dark sidebar for partnership specifics and a light main area for strategic benefits.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
15
The slide uses a list-based framework to demonstrate the 'Novel, Rapid, Effective' nature of their AI-driven discovery process.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
17
The table presents financial data in thousands of pounds (£'000) for the six months ended June 30th.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations Beat · Financials1 hit
35
BenevolentAI | Investor Presentation Deck | 46 slidesBenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
39
The slide uses a flowchart to illustrate the adaptive clinical trial design.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
32
The chart displays data from Bergamaschi et al. (2011) regarding acute CBD treatment for Social Anxiety Disorder (SAD).Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
33
The chart highlights the efficacy of CBD in reducing anxiety during the 'A' (Anticipation) and 'S' (Speaking) phases of the challenge.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
34
The chart highlights a statistically significant difference between CBD and Placebo groups during the speaking phase.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
35
The chart highlights the performance phase where the PH94B group shows a downward trend in distress compared to the placebo group.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
37
The chart highlights the 'Speech' phase with a box. SUDS is a standard clinical measure for anxiety.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations Beat · Traction1 hit
43
The table lists 13 rows, though the title mentions 12 trials; likely one trial is split or there is a discrepancy in the count.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
47
The slide uses a bar chart to compare placebo vs BNC210 across two metrics: total number of symptoms and symptom intensity.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
49
Includes references to specific clinical studies and behavioral tasks (JORT).Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
08
The slide highlights specific regional expansion efforts in Dallas-Fort Worth, New Orleans, and North Louisiana.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Loop · Day In Life1 hit
09
The slide highlights a 51% growth in average total AUM since the closing of the acquisition.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Loop · Day In Life1 hit
10
The slide uses a donut chart to visualize the split between sold and retained loan participations.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Loop · Day In Life1 hit
11
The table includes a breakdown of loans and deposits by region, comparing 2021 and 2022 figures with calculated growth and L/D ratios.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Loop · Day In Life1 hit
12
Includes detailed footnotes regarding non-GAAP financial measures.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank 1 hit
13
The slide uses a stacked area chart for regional composition and a waterfall chart for growth reconciliation.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank 1 hit
21
The slide uses a map to show physical locations and a timeline to show historical growth milestones.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Beat · Solution1 hit
26
The slide uses a combination of bar charts and overlay metrics to compare company performance against a defined 'Gulf South Peer Group'.Business First Bancshares | IPO Presentation Deck | 47 slides · Business First Bancshares
Pitch deck Investment bank Beat · Financials1 hit
10
The slide highlights clinical efficacy and safety data from a Nature Medicine study (Mackensen et al., 2022) relevant to the company's CABA-201 construct.Cabaletta Bio | Investor Presentation Deck | 23 slides · Cabaletta Bio
Pitch deck Investor relations 1 hit
16
Includes detailed scientific citations and specific cohort dosing strategies.Cabaletta Bio | Investor Presentation Deck | 23 slides · Cabaletta Bio
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
Includes regulatory status and financial terms of the licensing deal.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
14
Dare Bioscience | Investor Presentation Deck | 50 slidesDare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Financials1 hit
19
The slide highlights a key business development milestone involving a $10M upfront payment and potential $182.5M in milestones.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
27
Highlights the validation of the product by a major industry player (Bayer) and the financial terms of the deal.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit